Skip to content

Onglyza (Saxagliptin) Linked to Life-Threatening Heart Problems

Onglyza (containing saxagliptin) is a medication marketed to type 2 diabetes sufferers to manage their symptoms. Onglyza has been linked to an increased risk for heart failure (particularly among individuals with type 2 diabetes who also suffer from heart or kidney disease). If you or…

Published:

Onglyza (containing saxagliptin) is a medication marketed to type 2 diabetes sufferers to manage their symptoms. Onglyza has been linked to an increased risk for heart failure (particularly among individuals with type 2 diabetes who also suffer from heart or kidney disease).

If you or someone you know has been prescribed Onglyza and you are experiencing the following symptoms, please contact your physician immediately:

a man touching his heart, with heart pulse sign. Heart attack, a

Shortness of breath while engaging in everyday activities

  • Difficulty breathing while lying down
  • Drowsiness, fatigue, or weakness
  • Weight gain
  • Swelling in the ankles, feet, legs, and/or stomach regions

Those currently taking Onglyza should consult a medical professional prior to discontinuing use of the medication. If you or someone your care for has suffered an injury related to the use of Onglyza, please contact Inserra | Kelley | Sewell, Injury Attorneys for expert guidance and assistance recovering compensation for your injuries. Our experienced team of legal professionals are well-known for getting to the heart of the most painful liability/injury issues that our clients look to us to resolve.

Craig Kelley

Craig Kelley

A partner with Inserra | Kelley | Cooper | Sewell since 1993, Craig focuses on personal injury law with a large emphasis on motorcycle and bicycle-related cases, with the goal of first helping clients heal and then getting a speedy resolution.

All articles
Tags: Health

More in Health

See all
Acetaminophen Use in Pregnancy Linked to ADHD and Autism

Acetaminophen Use in Pregnancy Linked to ADHD and Autism

/

More from Craig Kelley

See all